Skip to main content

Exxon’s Safe Dividend Makes XOM Stock a Bargain Right Now

Exxon’s Safe Dividend Makes XOM Stock a Bargain Right NowExxon (NYSE:XOM) pays $3.48 per share in dividends to its shareholders. Will the dividend be cut? So far, not. So the dividend yield for XOM stock is 9.8%. This is a rare bargain.Source: Harry Green / Shutterstock.com Exxon has made no statement that it is cutting the dividend since the coronavirus pandemic ramped up. In fact, since the price of oil fell out of bed in the past two months, it has not indicated any such cut.It has been almost two months since Jan. 29 when Exxon last declared a $0.87 per share dividend. Moreover, this is the fourth quarterly dividend for XOM stock at this rate.InvestorPlace - Stock Market News, Stock Advice & Trading TipsExxon usually increases its quarterly dividend by the fifth quarter. The next quarterly dividend is not likely to be declared until late April or early May. * 10 Stocks to Buy That Will Benefit From Coronavirus Mayhem So if Exxon was going to signal a dividend cut it will happen within the next month or so. So far no bad news. Exxon Can Afford Its DividendLast year, Exxon generated almost $30 billion ($29.7 b) in free cash flow from operations (CFFO) before its capex spending. Since then the price of oil and gas has fallen at least 35 to 40% on average. So we can assume that going forward the CFFO will be at least $18 billion or so.Here is the thing. The dividend costs about $3.51 billion per quarter or $14 billion per year, and we haven't figured in the capex spending yet.Last year, Exxon spent a whopping $24.4 billion on capital expenditures. So, if the dividend and capex spending stay level, the company has to fund $48 billion. But it only produces $18 billion.At some point, Exxon has to address this shortfall. Maybe it thinks energy prices will rise. Or perhaps it will cut its capex spending drastically. Or lastly, Exxon could potentially handle the shortfall after capex spending with an increase in debt.Let's look at these possibilities. How Much Capex Can Exxon Cut?A Seeking Alpha author recently wrote an article describing how much capex the company could cut. He points out that in 2014 Exxon cut its capex from $30 billion to $10 to $15 billion a year within two years.The author feels that Exxon could do the same thing again within a year. He also feels that if the company needed to borrow to handle the transition, it could do so.He points out that the company has a very high interest coverage ratio. In addition, Exxon was able to borrow $1.25 billion in the commercial paper market with a low 2.4% coupon.So, theoretically, if CFFO stayed at $18 billion, which is not likely, and the dividend cost $14 billion, this would leave room for only $4 billion in capex. That is too low, and so Exxon would likely borrow $6 billion annually to cover capex spend of $10 billion for the year. The Bottom Line on XOM StockI am the first to point out that an abnormally high dividend yield is often the sign of an impending dividend cut. But in this case, I don't believe that will happen.For one, Exxon has stayed mum about a dividend cut. I believe it will likely keep the dividend level, and not raise it at the end of April, as might otherwise be expected.On the other hand, Exxon clearly has to address the issue of its huge capex spending. This cannot stay the same if the dividend is not going to be cut.In addition, most of the other major oil producers have already announced operating expense cuts, capex cuts, and buyback eliminations or cuts. Exxon does not have a significant buyback program. I expect that it will address these issues fairly soon.Until then, I would bet that XOM stock will be a good investment at these prices. It represents a huge bargain with its 9.8% dividend yield.As of this writing, Mark Hake, CFA does not hold a position in any of the aforementioned securities. Mark Hake runs the Total Yield Value Guide which you can review here. More From InvestorPlace * America's Richest ZIP Code Holds Wealth Gap Secret * 10 Stocks to Buy That Will Benefit From Coronavirus Mayhem * 5 Bank Stocks to Buy Now Because This Isn't 2008 Again * 12 Stocks to Buy That Are Already Positive The post Exxon's Safe Dividend Makes XOM Stock a Bargain Right Now appeared first on InvestorPlace.




from Yahoo Finance https://ift.tt/33V58vL

Comments

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be